184 related articles for article (PubMed ID: 29571994)
1. Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
Helfrich BA; Gao D; Bunn PA
Lung Cancer; 2018 Apr; 118():148-154. PubMed ID: 29571994
[TBL] [Abstract][Full Text] [Related]
2. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
5. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Spira AI; Iannotti NO; Savin MA; Neubauer M; Gabrail NY; Yanagihara RH; Zang EA; Cole PE; Shuster D; Das A
Clin Lung Cancer; 2012 Jan; 13(1):31-8. PubMed ID: 21862415
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F
Ann Oncol; 2017 Sep; 28(9):2241-2247. PubMed ID: 28911085
[TBL] [Abstract][Full Text] [Related]
10. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
Sampson VB; Vetter NS; Zhang W; Patil PU; Mason RW; George E; Gorlick R; Kolb EA
Oncotarget; 2016 Dec; 7(52):86594-86607. PubMed ID: 27863409
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
O'Shaughnessy J; Kaklamani V; Kalinsky K
Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Gitlitz BJ; Tsao-Wei DD; Groshen S; Davies A; Koczywas M; Belani CP; Argiris A; Ramalingam S; Vokes EE; Edelman M; Hoffman P; Ballas MS; Liu SV; Gandara DR
J Thorac Oncol; 2012 Mar; 7(3):574-8. PubMed ID: 22198425
[TBL] [Abstract][Full Text] [Related]
13. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.
Nakano T; Fujimoto K; Tomiyama A; Takahashi M; Achiha T; Arita H; Kawauchi D; Yasukawa M; Masutomi K; Kondo A; Narita Y; Maehara T; Ichimura K
Cancer Sci; 2022 Feb; 113(2):697-708. PubMed ID: 34839570
[TBL] [Abstract][Full Text] [Related]
14. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cortes J; Montero AJ; Glück S
Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
[TBL] [Abstract][Full Text] [Related]
15. Albendazole sensitizes cancer cells to ionizing radiation.
Patel K; Doudican NA; Schiff PB; Orlow SJ
Radiat Oncol; 2011 Nov; 6():160. PubMed ID: 22094106
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
17. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
18. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
19. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
[TBL] [Abstract][Full Text] [Related]
20. Eribulin, a microtubule inhibitor for metastatic breast cancer.
Wilkes GM
Oncology (Williston Park); 2011 Feb; 25(2 Suppl Nurse Ed):46-8. PubMed ID: 25373284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
